

<b>Name</b>	Teo Ziyun Winnie
<b>Current Position &amp; Affiliation</b>	1.Consultant, Department of Haematology Oncology, National University Cancer Institute (NCIS), National University Health System(NUHS), Singapore 2.Consultant, Alexandra Hospital, NUHS, Singapore 3.Clinical Assistant Professor, National University Singapore
<b>Country</b>	Singapore
<b>Major Field</b>	Haematology (Myeloproliferative Neoplasm, Myeloid Malignancies, Haemostasis and Thrombosis)

**Educational Background**

2019: FRCPath (Haematology), United Kingdom  
 2015-2018: Haematology Senior Residency Program, National University Health System (NUHS), Singapore  
 2013: MRCP, (Ireland)  
 2005-2010: National University of Ireland, Galway: MB BCh BAO- Republic of Ireland

**Professional Experience**

2021-current: Head of Division, Department of Haematology, Alexandra Hospital  
 2020: Myeloproliferative Neoplasms (MPN) Group- Tumour Group Lead, National University Cancer Institute, Singapore (NCIS), NUHS  
 2019-2021: Singapore Society of Haematology- Executive committee, Secretary  
 2017-2018: Chief Resident, Haematology Senior Residency Program, National University Cancer Institute, Singapore (NCIS), NUHS

**Other Experience and Professional Memberships**

Professional Memberships  
 -2022-current: Asian Myeloid Working Group  
 -2015-current: Singapore Society of Haematology

Others  
 -Advisory Board Meetings  
 -Ongoing Trials:

- P1101 in treating patients with early PMF or overt PMF at low or intermediate 1 risk - Principal Investigator
- SURPASS ET trial- Evaluating Ropoginteferon alfa 2b (P1101) for Essential Thrombocythaemia- Principal Investigator



---

## -Symposiums/Forums

2025: SDBCC Blood Cancer Symposium, Singapore-Invited speaker  
 2025: Asia Pacific Myeloid Forum, Hong Kong- Invited Speaker  
 2025: 40<sup>th</sup> Anniversary MPN Symposium, Singapore- Panelist  
 2025: MPN National Patient Forum, Singapore-Chairperson  
 2025: Optimizing Ropeginterferon alfa 2b use in MPN, Singapore- Invited Speaker  
 2024: MPN Asia, Japan-Invited speaker  
 2024: APAC MF alliance consensus steering committee  
 2024: Asian Myeloid Malignancies Exchange Forum, Hong Kong: Invited Speaker, Panelist  
 2024: Pathway to success: Optimizing treatment for MF, Singapore: Invited Speaker  
 2023: Asian Myeloid Malignancies Exchange Forum, Hong Kong: Panelist  
 2022: Asian Myeloid Malignancies Exchange Forum, Hong Kong: Panelist  
 2022: Myeloproliferative (MPN) New Horizons, Cross Country Webinar, Mumbai Haematology group: Invited Speaker/panelist  
 2022: MPN National Patient Forum, Singapore-Chairperson  
 2021: MPN Patient Journey Webinar- Invited Speaker

---

## Main Scientific Publications

### **Clinical Practice Recommendations for Myelofibrosis Management in the Asia-Pacific Region: The APAC-MF Alliance.**

Kirito K, Choi CW, Hein T, Hou HA, Jung CW, Kwong YL, Leung GMK, Ooi MGM, Rojnuckarin P, Ross DM, Shih LY, Takenaka K, Teo WZY, Gill H. JCO Oncol Pract. 2025 Jul 17:OP2400916

### **Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.**

Gill H, Leung GMK, Ooi MGM, Teo WZY, Wong CL, Choi CW, Wong GC, Lao Z, Rojnuckarin P, Castillo MRID, Xiao Z, Hou HA, Kuo MC, Shih LY, Gan GG, Lin CC, Chng WJ, Kwong YL. Clin Exp Med. 2023 Dec;23

---